Instem has issued a positive H1 update, indicating trading is progressing in line with expectations. The core preclinical market remains buoyant and opportunities around the SEND initiative continue to build ahead of the approaching first compliance deadline in December. Instem has also extended its contract with the market leader, Charles River Laboratories, until 2022, which helps underpin medium term expectations. We make no changes to our forecasts at this stage following the upgrades we put ....
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
N+1 Singer - Instem - In line trading update
- Published:
24 Aug 2016 -
Author:
Chris Glasper -
Pages:
3
Instem has issued a positive H1 update, indicating trading is progressing in line with expectations. The core preclinical market remains buoyant and opportunities around the SEND initiative continue to build ahead of the approaching first compliance deadline in December. Instem has also extended its contract with the market leader, Charles River Laboratories, until 2022, which helps underpin medium term expectations. We make no changes to our forecasts at this stage following the upgrades we put ....